ProVince Tx is the developer of novel oncolytic virus-based platforms for treating multiple forms of cancer. Its approach to immunotherapy is based on an oncolytic Adenovirus combined with tumour specific peptides, to deliver a rapidly adaptable therapy. ProVince Tx’s animal data support our hypothesis that the addition of tumour specific peptides to a proprietary oncolytic virus will be superior to existing viral therapies. PVTx is a spin-out company from the Division of Pharmaceutical Biosciences at the University of Helsinki, comprised of an internationally respected scientific founder with a strong track record in immunology research, backed by a highly experienced scientific and business team.